The Implications of Cost-effectiveness Analysis of Medical TechnologyCongress of the United States, Office of Technology Assessment, 1980 |
Other editions - View all
Common terms and phrases
39 Policy screening aBase accrue aged 30 Allocating Costs Application to Cervical assumptions Background Paper Benefits in Disease biopsy Blue Cross Carcinoma in situ case-finding CEA/CBA Cervical Cancer Screening clinic colposcopy Conization cost of screening Cost-Effectiveness Analysis Costs and Benefits Cryosurgery Death due Decision Tree diagnosis discount rate Disease Prevention Programs disease process disease transition dysplasia e₁ emigration estimates evaluation false-negative rate false-positive rate H₁ Health Program health promotion high-cost model High-risk Hysterectomy incidence rates invasive cancer invasive carcinoma joint production lesion Lives saved low-cost model Markov chain Medical Technology negative Office of Technology Pap smear Pap test error percent Policy screening intervals population positive postpone screening practitioners preclinical invasive preinvasive reported Respiratory Therapies savedb screening and treatment screening cost Screening policy screening screening program sector simulate society studies Technology Assessment test error rates tion tiveness Total cost transition probabilities U.S. Congress variables women